Compare Novartis AG (NVS) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Zillow Group Inc Class C — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Zillow Group Inc Class C trades at $31.8 (market cap $7.54B). The key difference: Novartis AG is far larger — about 38.5× Zillow Group Inc Class C's market cap, and Novartis AG pays a 3.17% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| NVS | Z | |
|---|---|---|
Market Cap | $290.25B | $7.54B |
Sector | Health | Media |
52-Week High | $168.62 | $90.35 |
52-Week Low | $113.50 | $29.41 |
Enterprise Value | $330.27B | $7.19B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Zillow Group (Z) trades at $33.03, down 2.58% amid legal headwinds, with technicals neutral and fundamentals showing improving profitability. Revenue grew to $2.58B in 2025 with net income turning positive at $23M, though valuation multiples remain elevated with a P/E of 132.04. The stock faces significant legal overhang from multiple class-action lawsuits alleging securities fraud related to an anticompetitive agreement.
The outlook is cautious; while earnings beat expectations in two recent quarters and analyst consensus targets $57.67, near-term risks from litigation and a high P/E ratio temper upside potential. Investment appeal hinges on legal resolution and sustained margin expansion beyond current modest levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
